166 related articles for article (PubMed ID: 20109727)
61. Uterine serous carcinoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Nout RA; Lorusso D; Vaughan MM; Bini M; Takano M; Provencher D; Indini A; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Candido Dos Reis FJ; Lopez S; Mariani A; Leitao MM; Raspagliesi F; Panici PB; Di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2021 Jul; 162(1):226-234. PubMed ID: 33934848
[TBL] [Abstract][Full Text] [Related]
62. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
[TBL] [Abstract][Full Text] [Related]
63. A 4-gene signature predicts prognosis of uterine serous carcinoma.
Chen H; Li L; Qin P; Xiong H; Chen R; Zhang M; Jiang Q
BMC Cancer; 2021 Feb; 21(1):154. PubMed ID: 33579221
[TBL] [Abstract][Full Text] [Related]
64. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
65. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
66. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
67. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
68. The role of matrix metalloproteinases-2, -7 and -9 and beta-catenin in high grade endometrial carcinoma.
Monaghan H; MacWhinnie N; Williams AR
Histopathology; 2007 Feb; 50(3):348-57. PubMed ID: 17257130
[TBL] [Abstract][Full Text] [Related]
69. A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Tran LKH; Tran PMH; Mysona DP; Purohit SB; Myers E; Lee WS; Dun B; Xu D; Liu H; Hopkins D; Nechtman J; Scelsi CL; Mittal PK; Kleven D; Wallbillich JJ; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2020 May; 157(2):340-347. PubMed ID: 32067813
[TBL] [Abstract][Full Text] [Related]
70. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
[TBL] [Abstract][Full Text] [Related]
71. Ryanodine receptor 1-mediated Ca
Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
[TBL] [Abstract][Full Text] [Related]
72. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
73. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
[TBL] [Abstract][Full Text] [Related]
74. Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract][Full Text] [Related]
75. Role of surgical staging and adjuvant treatment in uterine serous carcinoma.
Frey MK; Bashir S; Ward NM; Hensel KJ; Caputo TA; Holcomb KM; Baergen R; Gupta D
Eur J Gynaecol Oncol; 2013; 34(5):453-6. PubMed ID: 24475582
[TBL] [Abstract][Full Text] [Related]
76. The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.
Hillion J; Roy S; Heydarian M; Cope L; Xian L; Koo M; Luo LZ; Kellyn K; Ronnett BM; Huso T; Armstrong D; Reddy K; Huso DL; Resar LMS
Gynecol Oncol; 2016 Jun; 141(3):580-587. PubMed ID: 27001612
[TBL] [Abstract][Full Text] [Related]
77. Targeted therapy in the treatment of uterine serous carcinoma.
Schwab CL; Santin AD
Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
[No Abstract] [Full Text] [Related]
78. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
79. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
80. Controversies in the Management of Early-stage Serous Endometrial Cancer.
Larish A; Mariani A; Langstraat C
In Vivo; 2021; 35(2):671-680. PubMed ID: 33622859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
